The first human test of a rejuvenation method will begin “shortly”
-
The newsletter discusses Life Biosciences, cofounded by David Sinclair, receiving FDA approval for the first human trial of a "reprogramming" method aimed at age reversal. This technique, called ER-100, involves injecting genes into the eye to reset epigenetic controls and restore cells to a healthier state, initially targeting glaucoma. The trial represents a significant step in the longevity field, although potential risks and the limited scope are noted.
-
Key themes or trends:
- Age Reversal Research: Focus on techniques to reverse aging at the cellular level.
- Epigenetic Reprogramming: Using genes to reset cellular controls as a means of rejuvenation.
- Silicon Valley Investment: Significant funding flowing into longevity startups from tech billionaires.
- Clinical Trials: Moving from lab research to human testing of age-reversal therapies.
- Controversy and Skepticism: Differing scientific opinions on the effectiveness and safety of reprogramming.
-
Notable insights or takeaways:
- Life Biosciences' ER-100 treatment, based on Yamanaka factors, will be tested on glaucoma patients to rejuvenate eye cells, but carries risks of tumor formation and immune reactions.
- The "partial" or "transient" reprogramming approach aims to mitigate risks by limiting exposure to potent genes, but its long-term effects are still uncertain.
- While Sinclair is a prominent figure in longevity, he faces criticism regarding the exaggeration of scientific progress and the success of his ventures.
- Other companies are researching alternative gene combinations for reprogramming, emphasizing safety and side effects.
- The trial is considered a proof of concept, a starting point for age-reversal research rather than an immediate solution to aging.